| Your Source for the Latest Patent Information |
User Functions Categories- All
- Announcements (5)
- In The News (609)
- OG Notice Links (306)
- Patents of the Day (468)
Archives- December 2007 (18)
- November 2007 (36)
- October 2007 (45)
- September 2007 (36)
- August 2007 (36)
- July 2007 (44)
- June 2007 (36)
- May 2007 (45)
- April 2007 (36)
- March 2007 (36)
- February 2007 (39)
- January 2007 (44)
- more...
Search Syndication Credits- powered by b2evo
- skin cloned from Movable Type
|
GEN-ERIC Patent News
Your Source for the Latest Patent Information
08/29/06
7,100,190 Automobile web cam and communications system incorporating a network of automobile web cams  08/29/06
7,097,622 Non-invasive, quantitative somatosensory apparatus for the evaluation of erectile dysfunction  08/29/06
7,098,790 Electronic device attached to a pet  08/29/06
Apple Computer Inc. will pay $100 million to settle a dispute with Creative Technology Ltd. over patents covering technology used in digital music players, the companies said Wednesday. Cupertino-based Apple will pay Singapore-based Creative for a paid-up license to use Creative's recently-awarded patent in all Apple products. Creative had sued Apple for patent infringement, alleging iPods infringe Creative's patents. Apple countersued. Apple can recoup a portion of its payment if Creative is successful in licensing this patent to others, the companies said. In addition, Creative has joined Apple's "Made for iPod" program and will be announcing its own iPod accessory products later this year. "Creative is very fortunate to have been granted this early patent," said Steve Jobs, Apple's CEO. "This settlement resolves all of our differences with Creative, including the five lawsuits currently pending between the companies, and removes the uncertainty and distraction of prolonged litigation." Posted by GEN-ERIC at 12:24:13 am into the following categories: In The News08/29/06
A U.S. federal court has ruled that Samsung Electronics and Matsushita Electric Industrial did not infringe on each other's memory chip patents, Samsung said on Monday. The ruling by the court on Friday was related to one of a series of patent disputes between the two firms as they compete in the market for dynamic random access memory (DRAM) chips, used in personal computers, as well as flat panels. In the lawsuit filed in May 2002, Matsushita sought $300 million in damages from Samsung, accusing the South Korean company of infringing on three DRAM technology patents. "The New Jersey federal court in the United States ruled that both Samsung and Matsushita had not infringed on each other's patents," Samsung, the world's largest memory chip maker, told the Korea Exchange in a filing on Monday. But Matsushita rejected the ruling. "Samsung violated Matsushita's chip patents, and this ruling is unacceptable," said a spokesman from Matsushita, the world's largest consumer electronics maker. "We are studying necessary measures to overturn this verdict, including a possible appeal." Posted by GEN-ERIC at 12:22:51 am into the following categories: In The News08/29/06
Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP - News), a market leader in pain management, announced today that it has reached an agreement with The Purdue Frederick Company, The P.F. Laboratories, Inc., and Euro-Celtique, S.A. to settle long-running litigation claiming that Endo's oxycodone extended-release tablets, 10mg, 20mg, 40mg, and 80mg, a bioequivalent version of Purdue Frederick's OxyContin®, infringe Purdue's U.S. Patent Nos. 5,549,912, 5,508,042 and 5,656,295. Pursuant to the settlement, Endo will continue selling to its customers its oxycodone extended-release products until December 31, 2006. Endo, as well as its manufacturers, distributors, purchasers, and patients, will be released from all liability for infringement of Purdue's patents in connection with Endo's prior and future sales of these products. Though the settlement agreement will be submitted to the U.S. Federal Trade Commission and the Antitrust Division of the Department of Justice as required by statute, the release will survive unless overturned by a court order. Posted by GEN-ERIC at 12:21:46 am into the following categories: In The News08/29/06
A California biotechnology firm has voluntarily withdrawn an enzyme product from the market after losing a patent infringement lawsuit to Novozymes. Genencor International Inc., a Palo Alto, Calif.-based subsidiary of Danisco, has halted sales of Spezyme Ethyl, an alpha amylase enzyme. The decision follows a federal judge's ruling in a Delaware court that Genencor was selling enzymes protected by Novozymes' patent rights to the American ethanol market. Novozymes said in a written statement Friday that damages have yet to be decided in the case but that the company currently claims "several million" dollars for loss of profits. Novozymes, which was spun off from Novo Nordisk in 2000, develops enzymes for use in the manufacture of cellulosic-based ethanol. Posted by GEN-ERIC at 12:19:18 am into the following categories: In The News
|
Calendar| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| << < | > >> | |||||
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
LinksEmployment
USPTO
